Skip to main content

Table 1 Baseline characteristics by study arm

From: Somatic and sociodemographic predictors of depression outcome among depressed patients with coronary artery disease - a secondary analysis of the SPIRR-CAD study

  Intervention group (n = 285) Control group (n = 285)
Characteristics n/total valid n % n/total valid n %
Demographics
 Age, mean ± SD (total valid n), y 59.1 ± 9.8 (285)   59.3 ± 9.3 (285)  
 Female sex 61/285 (21.4) 59/285 (20.7)
 Married 170/268 (63.4) 185/271 (68.3)
Socioeconomic status
 Low 117/285 (45.0) 123/261 (47.1)
 Medium 84/285 (32.3) 71/261 (27.2)
 High 59/285 (22.7) 67/261 (25.7)
Baseline medical data
 Hypertension 252/281 (89.7) 245/280 (87.5)
 Hyperlipidemia 236/273 (86.4) 240/270 (88.9)
 Diabetes mellitus 69/275 (25.1) 70/279 (25.1)
 TSH, mean ± SD (total valid n), mU/l 1.6 ± 1.1 (187)   1.5 ± 1.2 (175)  
 BMI, mean ± SD (total valid n), kg/m2 28.5 ± 5.0 (280)   28.4 ± 4.8 (275)  
 Smokers 90/282 (31.9) 97/284 (34.2)
 Physically active 140/285 (49.1) 120/285 (42.1)
 Previous myocardial infarction 139/271 (51.3) 161/273 (59.0)
 Previous CABG 53/283 (18.7) 45/282 (16.0)
 Recent acute myocardial infarction 93/285 (32.6) 94/285 (33.0)
 Recent coronary intervention (PCI, CABG) 204/285 (71.6) 206/285 (72.3)
 NYHA class I-II 240/285 (84.2) 242/285 (84.9)
 NYHA class III 45/285 (15.8) 43/285 (15.1)
 Charlson Comorbidity Index, median (IQR) 2 (1/3) 2 (1/3)
 SF-36, mean ± SD (total valid n), 59.0 ± 24.9 (268)   55.6 ± 26.4 (271)  
Baseline medication
 Thyroid substitution 34/285 (11.9) 30/285 (10.5)
 Continued intake (until T3) 11/285 (3.9) 14/285 (4.9)
 Uric acid lowering agents 24/285 (8.4) 24/285 (8.4)
 Antibiotics 2/285 (0.7) 2/285 (0.7)
 ACE inhibitors 187/285 (65.6) 193/285 (67.7)
 Aspirin 257/285 (90.2) 262/285 (91.9)
 β-Blockers 246/285 (86.3) 257/285 (90.2)
 Statins 256/285 (89.8) 265/285 (93.0)
 Antidepressant medication 33/285 (11.6) 36/285 (12.6)
HADS-D depression subscale, mean ± SD (total valid n)
 Baseline 10.4 ± 2.5 (284)   10.4 ± 2.5 (284)  
 After 18 months (T3) 8.7 ± 4.1 (284)   8.9 ± 3.9 (285)  
  1. TSH Thyroid-stimulating hormone, BMI body mass index, CABG coronary artery bypass graft surgery, PCI percutaneous coronary intervention, NYHA New York Heart Association, IQR interquartile range, SF-36 Short Form Health Survey – physical functioning-36-item, ACE Angiotensin-converting enzyme, HADS-D Hospital Anxiety and Depression Scale - German version (depression subscale)